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Background: Chest pain remains a diagnostic challenge: physicians do not want to miss an acute coronary
syndrome (ACS), but, they also wish to avoid unnecessary additional diagnostic procedures. In approximately 75%
of the patients presenting with chest pain at the emergency department (ED) there is no underlying cardiac cause.
Therefore, diagnostic strategies focus on identifying patients in whom an ACS can be safely ruled out based on
findings from history, physical examination and early cardiac marker measurement. The HEART score, a clinical
prediction rule, was developed to provide the clinician with a simple, early and reliable predictor of cardiac risk. We
set out to quantify the impact of the use of the HEART score in daily practice on patient outcomes and costs.
Methods/Design: We designed a prospective, multi-centre, stepped wedge, cluster randomised trial. Our aim is to
include a total of 6600 unselected chest pain patients presenting at the ED in 10 Dutch hospitals during an 11-month
period. All clusters (i.e. hospitals) start with a period of ‘usual care’ and are randomised in their timing when to switch
to ‘intervention care’. The latter involves the calculation of the HEART score in each patient to guide clinical decision;
notably reassurance and discharge of patients with low scores and intensive monitoring and early intervention in
patients with high HEART scores. Primary outcome is occurrence of major adverse cardiac events (MACE), including
acute myocardial infarction, revascularisation or death within 6 weeks after presentation. Secondary outcomes include
occurrence of MACE in low-risk patients, quality of life, use of health care resources and costs.
Discussion: Stepped wedge designs are increasingly used to evaluate the real-life effectiveness of non-pharmacological
interventions because of the following potential advantages: (a) each hospital has both a usual care and an intervention
period, therefore, outcomes can be compared within and across hospitals; (b) each hospital will have an intervention
period which enhances participation in case of a promising intervention; (c) all hospitals generate data about potential
implementation problems. This large impact trial will generate evidence whether the anticipated benefits (in terms of
safety and cost-effectiveness) of using the HEART score will indeed be achieved in real-life clinical practice.
Trial registration: ClinicalTrials.gov 80-82310-97-12154.
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Table 1 Elements to calculate HEART score for chest pain
patients at the emergency department
History Highly suspicious 2
Moderately suspicious 1
Slightly or non-suspicious 0
ECG Significant ST-depression 2
Nonspecific repolarization disturbance 1
Normal 0
Age ≥ 65 years 2
>45 – <65 years 1
≤ 45 years 0
Risk factors ≥ 3 risk factors*, or history of atherosclerotic disease^ 2
1 or 2 risk factors 1
No risk factors known 0
Troponin ≥ 3x normal limit 2
>1 - <3x normal limit 1
≤ normal limit 0
Total
Range: 0-10
*Risk factors include: currently treated diabetes mellitus, current or recent
smoker, diagnosed and/or treated hypertension, diagnosed
hypercholesterolemia, family history of coronary artery disease (CAD) , obesity
(body mass index (BMI) >30).
^History of atherosclerotic disease include: coronary revascularization,
myocardial infarction, stroke, or peripheral arterial disease, irrespective of the
risk factors for CAD.
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Patients presenting with chest pain at the emergency de-
partment (ED) pose a diagnostic challenge. Chest pain can
be a symptom of an acute coronary syndrome (ACS), i.e.
acute myocardial infarction (AMI) or unstable angina,
which is the case in approximately 20% of the patients and
requires prompt treatment. In the remaining 80%, chest
pain is caused by many other, usually not life-threatening,
conditions [1]. Unfortunately, decision-making in chest
pain patients is hampered by limited predictive power of
patient characteristics, including signs, symptoms and
additional tests [1-3]. Therefore, physicians face the chal-
lenge of not wanting to miss an ACS on the one hand,
while avoiding too many unnecessary diagnostic proce-
dures that can be time-consuming and patient burdening
on the other hand. Currently, the fear of missing a relevant
cardiac condition makes physicians cautious and, to be on
the safe side, a large proportion of patients are kept in the
hospital from several hours to days for monitoring or add-
itional testing.
Diagnostic strategies in patients with chest pain there-
fore focus on identifying patients in whom ACS can be
safely ruled out based on readily available clinical findings
from history, physical examination and early marker
measurement of cardiac damage. Recent guidelines sug-
gest the use of well-developed and validated risk scores to
stratify patients in the emergency room [4-6]. Several
prognostic risk scores have been developed for patients di-
agnosed with ACS, such as the TIMI (Thrombolysis in
Myocardial Infarction) risk score and the GRACE (Global
Registry of Acute Cardiac Events) risk score [7-9]. How-
ever, scores that identify ACS in patients suspected of ACS
in the emergency setting and predict short-term mortality
or coronary intervention are not available. The HEART
score has been specifically developed for risk stratification
in all patients with chest pain presenting at the ED.
The HEART score incorporates all five important ele-
ments of clinical judgement in chest pain patients: History,
ECG (electrocardiogram), Age, Risk factors and Troponin
(see Table 1). Similar to the Apgar score, applied world-
wide to assess the need for intensive care in new-borns
[10], each of the five elements is appreciated with 0, 1 or 2
points. The sum of all five elements results in a score be-
tween 0–10, which can easily be calculated.
The HEART score has been externally validated in vari-
ous patient populations with a total of 6174 patients and
its predictive effectiveness has been demonstrated [11-14].
Table 2 depicts an overview of these validation studies. In
the Dutch multicenter validation study, major adverse car-
diac events (MACE) occurred in 1.7% (95% CI 1.18-2.22)
of all patients with a HEART score of 3 or lower. This is
comparable with the around 2% incidence of ACS among
discharged chest pain patients reported in the literature
[15,16]. Importantly, none of the patients in the low-riskHEART category experienced unexpected sudden cardiac
death in our validation studies. MACE occurred in 16.6%
of all patients with intermediate HEART scores (4–6), and
in 50.1% of all patients with high HEART scores (7–10).
Similar results were observed in relevant patient sub-
groups, such as women, elderly or diabetics [12]. Notwith-
standing these promising validation results, the impact of
the use of the HEART score in daily clinical practice re-
mains to be established. The HEART score provides the
physician with a formal risk score and a recommendation
whether a chest pain patient should be admitted or not. A
safe and early discharge could potentially result in a sig-
nificant reduction of patient burden, hospital admissions
and health care costs.
Therefore, we designed the HEART Impact study to in-
vestigate whether the use of the HEART score in the man-
agement of chest pain patients indeed leads to these
positive health effects, while not causing an increase in the
occurrence of MACE.
Methods/Design
Study design: stepped wedge randomised trial
We will use a prospective, stepped wedge cluster ran-
domised trial [17,18]. Our aim is to include 6600 unselected
chest pain patients from 10 hospitals in the Netherlands
during an 11-month period. Key study design features are
Table 2 Summary of results of previous validation studies of the HEART score
Total
Number of patients N = 880 [12] N = 2388 [13] N = 2906 [14] N = 6174
Design Retrospective Prospective Prospective
Countries The Netherlands The Netherlands 9 countries in the Asia-Pacific region
Participating hospitals 4 10 14
Inclusion period Jan ‘06 – Mar ‘06 Oct ‘08 –Nov ‘09 Nov ‘07 – Dec ‘10
Type of patients Patients presenting with chest
pain at the ED
Patients presenting with chest
pain at the ED
Patients presenting with chest pain
at the ED
MACE definition AMI, revascularisation,
all cause death
AMI, revascularisation, stenosis
managed conservatively, all cause death
AMI, revascularisation, death unless
clearly non-cardiac
Duration of follow-up 6 weeks 6 weeks 4 weeks
Cumulative incidence of MACE stratified by
HEART scores
0-3 0.99% 1.7% 1.7% 1.6% (95%-CI 1.05-2.15)
4-6 11.6% 16.6% 14.3% 12.5% (95%-CI 11.34-13.66)
7-10 65.2% 50.1% 50.0% 49.4% (95%-CI 46.37- 52.43)
ED: emergency department.
AMI: acute myocardial infarction.
MACE: major adverse cardiac event.
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is no randomisation at patient level, but hospitals will be
randomised with respect to the timing at which they intro-
duce the HEART score. See Figure 1. During the first
month, all chest pain patients presenting to the ten hospi-
tals will receive usual care. Then, during a 10-month
period, each month one randomly allocated hospital will
start to apply the HEART score (HEART period) and con-
tinue to do so until the end of the study. During the last
month of the inclusion period all 10 hospitals will be using
the HEART score.
‘Usual care’ and ‘HEART’ period
Usual care is defined as ‘daily practice of the cardiologist or
attending emergency doctor to diagnose a patient with
chest pain’. In this period, attending doctors assess the risk
based on their clinical skills, previous experiences, gut feel-
ing and various other criteria (for example, described in
European Society of Cardiology Guidelines [6]), without
using the HEART score. No attempt was made to explicitly
standardise usual care across all hospitals. The assessment
will typically include: gender, age, medical (cardiac) history,
symptoms, risk factors, and current drug use, physical
examination with special attention for the heart and lungs,
blood pressure, heart rate, blood tests, ECG, and any other
diagnostic procedures the physician considers necessary.
The standard blood tests include measurements of tropo-
nin, glucose levels, creatinin levels (with a calculated esti-
mated glomerular filtration rate (eGFR) according toFigure 1 The Stepped Wedge Design for the HEART Impact study.MDRD (modification of diet in renal disease)), haemoglo-
bin, and any other blood test required. A standard 12-lead
ECG is recorded by a trained employee of the ED and clas-
sified by a single cardiologist according to the Minnesota
coding criteria. All investigations take place in the ED.
During the HEART period, the HEART score will be for-
mally determined in all patients. Decision-making about
whether to admit a patient, any further testing or treatment
decisions will be carried out similarly to usual care, with
the exception of the availability of the HEART score in
each individual patient and the recommendations linked to
that score. This is also known as “directive use” of a predic-
tion rule, as opposed to “assistive use” where only the
predicted risk is given to the physician [19]. The recom-
mendation for patients with a HEART score of 3 or lower
will be reassurance and discharge. In those low-risk pa-
tients who are discharged, a second troponin will be
performed at home to identify any missed ACS. A similar
approach of home visits performed by ambulatory lab ser-
vices was successfully applied in our earlier study in
suspected ACS in primary care [20]. Obviously, in accord-
ance with daily practice, the attending physician may de-
cide to overrule the recommendation corresponding to a
low HEART score and admit a patient. In such a case, in-
formation about the reasoning for this escape will be col-
lected. Patients with a HEART score in the intermediate
range (4–6), will generally be admitted to the hospital for
further observation and investigation. The high-risk group
(7–10) will typically receive prompt (invasive) treatments.
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All patients above 18 years presenting with chest pain to
the (cardiac) ED of 10 participating hospitals are eligible.
Only patients presenting with evident ST-segment eleva-
tion myocardial infarction (STEMI) will be excluded, since
there is no diagnostic dilemma in these patients. Typically,
such patients are directly taken to the intervention room.
In both study periods, information about the study pro-
cedure will be provided by the treating physician and writ-
ten consent for the use of data and follow-up is obtained
at the first appropriate moment after presentation at the
ED. In the HEART period, no consent from the patient is
needed for the use of the HEART score, for several rea-
sons. First, the number of additional procedures for pa-
tients is minimal since the HEART score consists of
elements that are collected routinely. Furthermore, the
HEART score is proven to be safe, and is a decision
support tool rather than a real intervention, with the pos-
sibility for physicians to override the recommendations
provided by the rule. The study was approved by the Insti-
tutional Review Board, and subsequently by the Boards of
the participating hospitals.
Outcome measures
The HEART impact trial aims to measure both the
intended positive changes as well as any unintended nega-
tive effects associated with the use of the HEART score.
Patient outcomes, use of health care resources and costs
will be determined in both periods.
Primary outcome: occurrence of MACE
The primary outcome is the 6-week occurrence of major
adverse cardiac events (MACE), consisting of the follow-
ing events: acute myocardial infarction (AMI), Percutan-
eous Coronary Intervention (PCI), Coronary Artery
Bypass Grafting (CABG) surgery, or death due to any
cause. To identify MACE after discharge, a phone-call willFigure 2 Flow of study and data collection in usual care period and in
EQ-5D: EuroQol Five-Dimensional. SF-36: short-form 36. iPCQ: productivity cbe made to all patients at home after 3 months. Any infor-
mation that could indicate to possible endpoints will be
further investigated through hospital charts, hospital dis-
charge letters and information obtained from the patient’s
general practitioner (GP). In addition, the Central Bureau
for Statistics (CBS) will be consulted for information on
vital status as the cause of death of participants. All
cases with possible endpoints are reviewed by two inde-
pendent adjudicators for endpoint classification. This
adjudication committee will evaluate all relevant infor-
mation to decide, using ESC guidelines, whether MACE
occurred. In case of disagreement between two adjudi-
cators, the case is discussed in a plenary adjudication
committee meeting until consensus is reached.
Secondary outcomes include the following:
 The occurrence of MACE in the specific subgroup
of patients with a low HEART score.
 Use of health care resources. The number of hospital
admissions/discharges, duration of hospital stay,
duration of stay on the ED, number of readmissions
and GP visits after discharge will be collected.
 Health-related quality of life. This will be
determined in a subset of approximately 1000
patients, in both time periods in five of the
participating hospitals. Data on health-related
quality of life are collected at baseline (at ED) using
the EuroQol Five-Dimensional (EQ-5D)
questionnaire, and a 2-week and at 3-month follow-
up using the short form-36 (SF-36) and the EQ-5D
questionnaires. SF-36 is a short-form health survey
with only 36 questions. For this study, we will only
use the 11 questions addressing Health. EQ-5D
comprises the following 5 dimensions: mobility, self-
care, usual activities, pain/discomfort and anxiety/
depression. Furthermore, the EQ VAS (visual
analogue scale) records the respondent’s self-ratedHEART period. ED: emergency department. QoL:quality of life.
ost questionnaire. MACE: major adverse cardiac events.
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endpoints are labelled ‘Best imaginable health state’
and ‘Worst imaginable health state’. Higher scores are
associated with a better health-related quality of life.
 Direct and indirect costs. These will be determined
in a subset of approximately 1000 patients, in both
time periods in five of the participating hospitals.
Actual medical costs using a health-care provider’s
perspective are obtained in both the time periods.
Medical resource use is extracted from the
electronic hospital patient files. Unit cost prices will
be determined in two participating hospitals, one
academic and one peripheral hospital, using micro-
costing if possible and top down costing otherwise.
The iPCQ (Productivity Cost Questionnaire) will be
used to collect quantitative data on the relation
between illness, treatment and work performance.
The iPCQ is divided into 3 modules: (1) reduced
productivity at paid work due to work absenteeism,
(2) reduced productivity at paid work without absence
from work and (3) unpaid labour production.
 An additional sample of blood will be collected from
patients of two participating hospitals during the
emergency visit for future biomarkers investigation
(Biobanking).
Statistical analyses
The 6-week cumulative incidence of MACE in both the
intervention and usual care period will be analysed at the
patient level using a generalised linear mixed model
(GLMM) [21]. Risk differences with corresponding 95%
CIs will be estimated from this model. No baseline differ-
ences in prognostic factors between patients included in
both periods are expected, but in case these do occur, co-
variates will be added to the GLMM model to adjust for
these baseline differences. Differences in health-related
quality of life at baseline, 2 weeks and at 3 months will
also be assessed, separately for the different question-
naires. Costs per patient will be calculated according to
Dutch guidelines for pharmaco-economic analyses [22],
and costs of drugs prescribed will be based on Dutch for-
mulary cost-prices.
Sample size
The aim of the HEART study is to evaluate whether the
use of the HEART score streamlines the further manage-
ment of chest pain patients, in particular whether it can
identify low-risk patients who can be discharged sooner
than usual. However, these benefits become only rele-
vant if the use of the HEART score does not lead to an
increase in adverse cardiac events. Our sample size cal-
culation is therefore based on demonstrating that pro-
portion of patients with MACE is not inferior to the
proportion observed with usual care. The proportionMACE expected during usual care is 17%. The non-
inferiority margin is based on clinical judgement and avail-
able literature as 3%, thus accepting an upper limit of the
95% confidence interval (CI) during the intervention
period of 20%. With 10 hospitals, inclusion of 60 patients
per hospital per month, a between-hospital variation in in-
cidence of 16 to 18%, a one-sided alpha of 5% and a power
of 80%, 6600 patients with chest pain should be included
in total. Taken into account our inclusion rates of previous
validation studies and with special attention and encour-
agement for inclusion, we expect a realistic inclusion rate
of 60 patients per hospital per month.
Cost-effectiveness analysis
A cost-effectiveness analysis will be performed from a soci-
etal perspective, for a 3-month and a life-time time hori-
zon. The 3-month time horizon corresponds to the actual
follow-up period and will consider the observed differences
in costs and quality of life. A GLMM will be used to assess
cost-effectiveness, accounting for the randomisation of
clusters instead of patients. Uncertainty will be addressed
through the GLMM model which will be extended with
cluster and patient-level covariates if baseline characteris-
tics are imbalanced. The life-time horizon will be applied
to account for long-term costs and effects of the observed
MACE. Here, the observed risks of MACE, as well as the
direct treatment cost and productivity losses estimated
using the friction cost approach, will serve as input for a
Markov decision-analytic model [23]. If necessary, add-
itional evidence on long-term costs and effects of adverse
events will be obtained from the literature. Monte Carlo
simulation will be applied to simulate the course of hypo-
thetical patients through the model, and to estimate the
number of quality-adjusted life years and costs of both
strategies. Costs will be discounted with 4% per annum,
and effects with 1.5% per annum, according to Dutch
guidelines. The incremental cost-effectiveness ratio and the
net monetary benefit (for various willingness to pay thresh-
olds) will be estimated for the HEART score compared
with usual care. Uncertainty will be assessed with prob-
abilistic sensitivity analysis [24], and results will be
presented in incremental cost-effectiveness planes and
cost-effectiveness acceptability curves.
Regulation statement
This study will be conducted according to the principles
of the current version of the declaration of Helsinki and in
accordance with the Dutch law on Medical Research In-
volving Human Subjects Act (WMO).Ethics committee approval
The study was approved by the Institutional Review Board
(medical ethical committee of the University Medical
Table 3 Overview of key characteristics of the stepped wedge design
(i)→ Stepped wedge design has features of cluster randomisation, i.e. during a specific time period only type of
intervention (usual care or HEART score) is administered
a.→ This reduces the risk of contamination
b.→ The effect of clustering needs to be taken into account in the statistical analysis
(ii)→ Stepped wedge design has features of a one direction cross-over trial, i.e. each hospital contributes data from
both usual care and HEART score in a fixed order.
a.→ Allows for comparison of results within hospitals which may be less confounded by differences in case mix
than between hospitals
b.→ The fixed order from usual care to HEART score further reduces the risk of contamination as the HEART score
is relatively simple to calculate.
c.→ Due to the cross-over, each hospital will provide data about the (problems in) implementation of the HEART score
(iii)→ Switch from usual care to HEART score in hospitals is evenly and randomly distributed over calendar time
a.→ This reduces the impact of potential changes over time in other factors than the intervention
b.→ It facilitates the close monitoring and logistic of all activities surrounding the switch
(iv)→ Gradual implementation of new strategy is carried out, thereby providing data about the process itself.
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Boards of the participating hospitals.
Discussion
Clinical prediction rules, like any other health care inter-
vention, need proper evaluation before wide-spread use in
clinical practice. Two key steps in this evaluation include
external validation and impact assessment. External valid-
ation studies can reveal several problematic issues associ-
ated with the use of a clinical prediction rule [25-27].
Firstly, the rule has been developed on a dataset that was
too small in relation to the number of variables that have
been considered. This increases the risk that particularities
of the dataset will be modeled rather than robust relation-
ships. The consequence is that the performance of the
model will decrease when applied to new patients (exter-
nal validation). This is known as over-fitting. Secondly, the
rule has been derived in a population which does not
match the population where clinicians would like to use
the rule. Here, your prediction model may be developed
statistically sound, but applied to a new population the
performance may decrease meaningfully. However, even
after proper development and good performance in valid-
ation studies, often clinical prediction rules are hardly or
incorrectly used in daily practice, because of difficulties in
application or because physicians are not convinced of its
usefulness in clinical practice. This is especially the case
when the outcome used in the rule has no direct relevance
for clinical practice. For all these reasons, it is of vital im-
portance to study the impact of a clinical prediction rule
when applied in real-life practice. Increasingly, stepped
wedge designs are applied to measure the impact of clin-
ical decision rules in clinical practice [28]. The stepped
wedge design combines elements of both the cluster
randomised trial and the before-after design (see Figure 1).
The stepped wedge design has several features that makethis design attractive for such impact studies. These char-
acteristics are outlined in Table 3. We chose the stepped
wedge design as an informative, efficient and valid design
to examine whether expected improvements in patient
outcomes, use of health care resources, and costs can be
achieved when implementing a health care intervention
on a large scale.
Conclusion
It is of importance to generate valid evidence that the use
of the HEART score compared to usual care is safe and
leads to fewer admissions and diagnostic procedures in
real-life clinical practice. Using the stepped wedge design,
we can also monitor the process of implementation of a
clinical support tool at the ED across hospitals that vary in
size and population. Patient inclusion has started July 1st
of 2013.
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